Atypical chronic myeloid leukemia - aCML
aCML was initially described as a subtype of myeloid neoplasm closely resembling CML, but lacking the pathognomonic Philadelphia chromosome.
Articles
Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?
July 6, 2022, Cureus
Ruxolitinib Well-Tolerated, Active in Patients with CNL and Atypical CML
January 24, 2020, Oncology Learning Network
Atypical chronic myeloid leukemia achieving good response with azacytidine
October 2019, PubMed
TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS HARBORING ATYPICAL BCR-ABL1 TRANSCRIPTS
June 2019, Hemasphere
How I Treat In Brief: Atypical Chronic Myeloid Leukemia
September 1, 2017, ASH Clinical News
Atypical Chronic Myeloid Leukemia: Current Research and Treatment Strategies
April 17, 2017, Cancer Therapy Advisor
Atypical CML Distinct From Related Myelodysplastic/Myeloproliferative Disorders
May 7, 2014, CancerNetwork
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms
April 24, 2014, Journal Blood
The First Case of Decitabine Successfully in Treatment of Atypical Chronic Myeloid Leukemia with CEBPA Double Mutation
2013, Omicsgroup
Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis
July 2012, PubMed